drugset / Trial / NCT05844111

A Study to Investigate the Absorption, Metabolism and Excretion of [14C]-BGB-11417

NCT05844111

Phase 1 Completed 6 enrolled BeiGene
NaSingle-groupOpen-labelOther

Summary

The main objective of this study is to determine the mass balance, routes of elimination, and pharmacokinetics of \[14C\]-BGB-11417 in healthy male participants along with determining the concentrations of radioactivity in plasma, fecal and urinary elimination of total radioactivity.

Timeline

Start
2023-05-22
Primary completion
2023-06-18
Completion
2023-06-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Sonrotoclax Other / unclassified Oral

Indications

No indication recorded.